A Phase 2, 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Nov 2017
At a glance
- Drugs SM 04690 (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- Sponsors Samumed
- 16 Nov 2017 Planned End Date changed from 1 Mar 2018 to 1 Apr 2018.
- 16 Nov 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Apr 2018.
- 16 Nov 2017 Status changed from recruiting to active, no longer recruiting.